May 31, 2022 -- A proprietary platform from Decibel Therapeutics is helping to break down the barriers to understanding the molecular pathways and cell physiology inside the inner ear by integrating single-cell genomics, bioinformatic analyses, and precision gene therapy technologies, contends CEO Laurence Reid, PhD.
The biotech company is working on treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine, Reid told ScienceBoard.net at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC.
"Many people usually think about hearing as a quality-of-life issue and I try to avoid using that phrase, because I think it's really fundamental to cognitive health overall, development early in life, and maintenance of that later in life," Reid said, noting that regenerating hair cells is the "holy grail" for both hearing and balance therapies.
At ASGCT 2022, Decibel Therapeutics presented pre-clinical animal data on its lead investigational gene therapy, DB-OTO, being developed to restore hearing to individuals with a mutation in the otoferlin gene.
Watch the video recording below to learn more.
Copyright © 2022 scienceboard.net